Oncternal Therapeutics to delist from Nasdaq, deregister with SEC

Written by Emily J. Thompson, Senior Investment Analyst

ONCT%

Updated: Mar 07 2025

0mins

Oncternal Therapeutics Delisting: Oncternal Therapeutics plans to file a Form 25 Notification of Delisting with the SEC on March 17, 2025, to remove its securities from Nasdaq listing and registration.
Voluntary Action Following Suspension: The company is taking this step voluntarily after Nasdaq suspended trading of its common stock on December 3, 2024, and aims to deregister with the SEC by filing a Form 15.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Oncternal Therapeutics to delist from Nasdaq, deregister with SEC

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Top Growth Stocks to Buy Now: Nvidia, Amazon, Dutch Bros

Bitcoin's Market Cap Exceeds $1.9 Trillion, Potential to Reach $1.2 Million

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch